Please select the outcome measures that correspond to the clinical trial below.
Title: A Randomized Study Combining Etanercept and Short Courses of Narrow-Band UVB in Patients With Psoriasis Vulgaris
Brief Summary: This study will provide data on the addition of narrow band ultra violet B (nbUVB) phototherapy to participants who have not shown an excellent response to three months of etanercept.


Options:
A: Percentage of Participants Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI 75) Score at Week 12 (Week 12)
B: Single Ascending Dose (SAD) Cohort: Change From Baseline in Blood Pressure at Day 1 (Baseline, 24 hours post-dose on Day 1); Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Blood Pressure at Day 10 (Baseline, 16 hours post-dose on Day 10); Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Blood Pressure at Day 28 (Baseline, 16 hours post-dose on Day 28); Single Ascending Dose (SAD) Cohort: Change From Baseline in Pulse Rate at Day 1 (Baseline, 24 hours post-dose on Day 1); Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Pulse Rate at Day 10 (Baseline, 16 hours post-dose on Day 10); Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Pulse Rate at Day 28 (Baseline, 16 hours post-dose on Day 28); Single Ascending Dose (SAD) Cohort: Change From Baseline in Oral Temperature at Day 1 (Baseline, 24 hours post-dose on Day 1); Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Oral Temperature at Day 10 (Baseline, 16 hours post-dose on Day 10); Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Oral Temperature at Day 28 (Baseline, 16 hours post-dose on Day 28); Number of Participants With Change From Baseline in Physical Examinations (SAD Cohort: Baseline up to Day 8, MAD Cohort: Baseline up to Day 28, MAD Psoriasis Cohort: Baseline up to Day 56, Food Effect Cohort: Baseline up to Day 37); Single Ascending Dose (SAD) Cohort: Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) at Day 1 (Baseline, 24 hours post-dose on Day 1); Multiple Ascending Dose (MAD) Cohort: Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) at Day 10 (Baseline, 16 hours post-dose on Day 10); Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) at Day 28 (Baseline, 16 hours post-dose on Day 28); Single Ascending Dose (SAD) Cohort: Change From Baseline in Heart Rate at Day 1 (Baseline, 24 hours post-dose on Day 1); Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Heart Rate at Day 10 (Baseline, 16 hours post-dose on Day 10); Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Heart Rate at Day 28 (Baseline, 16 hours post-dose on Day 28); Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Discontinuation Due to AEs (SAD Cohort: Baseline up to Day 8, MAD Cohort: Baseline up to Day 28, MAD Psoriasis Cohort: Baseline up to Day 56, Food Effect Cohort: Baseline up to Day 37); Number of Adverse Events (AEs) According to Severity (SAD Cohort: Baseline up to Day 8, MAD Cohort: Baseline up to Day 28, MAD Psoriasis Cohort: Baseline up to Day 56, Food Effect Cohort: Baseline up to Day 37); Number of Participants With Laboratory Abnormalities (SAD Cohort: Baseline up to Day 8, MAD Cohort: Baseline up to Day 28, MAD Psoriasis Cohort: Baseline up to Day 56, Food Effect Cohort: Baseline up to Day 37); Single Ascending Dose (SAD) Cohort: Change From Baseline in Creatinine Clearance at Day 1 (Baseline, 24 hours post-dose on Day 1); Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Change From Baseline in Creatinine Clearance at Day 10 (Baseline, 16 hours post-dose on Day 10); Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Creatinine Clearance at Day 28 (Baseline, 16 hours post-dose on Day 28); Food Effect Cohort: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06700841 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post dose on Day 1); Food Effect Cohort: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-06700841 (pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post dose on Day 1); Food Effect Cohort: Maximum Observed Plasma Concentration (Cmax) of PF-06700841 (pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post dose on Day 1)
C: Number of Participants Attaining a 90 Percent Reduction in PASI From Baseline (PASI 90) - ITT (112 and 140 days)
D: Percentage improvement of PASI from baseline to Week 16 (Week 16)

Answer: C